

FP7–NANOMMUNE Closing Workshop

Understanding Nano–Immuno–Interactions

June 17, 2011

City Conference Center at Norra Latin, Stockholm, Sweden

First announcement



Adapted from <http://365photopaths.blogspot.com/2010/05/stockholm-skylines-reflections.html>

Harri Alenius

Finnish Institute of Occupational Health, Helsinki, Finland

Diana Boraschi

National Research Council, Pisa, Italy

Valerian Kagan

Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA

Fritz Krombach

Ludwig-Maximilians-Universität München, München, Germany

Riitta Lahesmaa

University of Turku, Turku, Finland

Andrew Maynard (*Keynote Speaker*)

University of Michigan School of Public Health, Ann Arbor, MI

Victor Puentes

Institut Català de Nanotecnologia, Barcelona, Spain

Barbara Rothen-Rutishauser

University of Bern, Bern, Switzerland

Rob Vandebriel

National Institute for Public Health and the Environment, Bilthoven, The Netherlands

Annika Scheynius

Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Anna Shvedova

National Institute for Occupational Safety and Health, Morgantown, WV

Engineered nanomaterials (ENs) have fundamentally different properties compared to their bulk counterparts and offer great opportunities for diverse technological and biomedical applications. These properties enable unique interaction of ENs with biological systems, and consequently these materials could also exert adverse effects on human health. Understanding the interactions of ENs with biological systems is a key challenge in nanosafety research and could lead not only to the mitigation of EN-induced toxicities but may also promote safe biomedical applications of these novel materials for diagnosis and treatment of human disease. The immune system protects us from foreign materials and microbes, and understanding the mechanisms and consequences of nano-immuno-interactions is of central importance. The FP7-NANOMMUNE Closing Workshop focuses on the interaction between ENs and the immune system and features leading international experts in nanotoxicology, immunology, systems biology (transcriptomics), and material sciences. The Keynote Lecture is presented by Prof. Andrew Maynard, a member of the Advisory Board of the NANOMMUNE consortium. Key results from the FP7-NANOMMUNE project are reported.

FP7-NANOMMUNE is funded by the European Commission through the Seventh Framework Programme. The aim of the project is to elucidate the putative adverse effects of engineered nanomaterials on the immune system through a comprehensive, multi-disciplinary approach involving partners in both Europe and the United States.

Organizer and Chairman:

Prof. Bengt Fadeel, Karolinska Institutet

More information: www.nanommune.eu

Participation is limited to 100 persons. Registration deadline: April 30, 2011 (erika.witasp@ki.se)

